At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in triple therapy. This study explores a non-antibiotic treatment regime for H.pylori that uses lauric acid as the primary anti-microbial agent. The study hypothesis is that Lauric acid works synergistically with omeprazole following administration of a mucolytic agent to kill H.pylori topically in the stomach.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
33
GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
Singapore General Hospital
Singapore, Singapore
Number of Participants With Eradication of H.Pylori Infection
Eradication as measured by negative Urea Breath Test 4-6 weeks following completion of treatment
Time frame: 4-6 weeks following treatment
Absence of Significant Gastric Abnormality Post-treatment (Initial Phase)
Gastroscopy pre- and post-treatment will be performed in the Initial Phase (20 participants), with the goal of excluding significant gastric abnormality at baseline and after treatment (e.g. gastric ulceration arising following the treatment).
Time frame: up to 14 days of treatment
Assessment of Adverse Events (AE)
Adverse event data will be collected in response to neutral questioning.
Time frame: AE commencing within 30 days of initiation of treatment, followed until resolution
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.